It was reported yesterday that the United States Food and Drug Administration (USFDA) has granted approval to India-based Sun Pharmaceutical Industries for its dry eye disease treatment CEQUA (cyclosporine ophthalmic solution) 0.09%.
The product increases tear production in patients with keratoconjunctivitis sicca. It reportedly offers the highest FDA-approved concentration of cyclosporine A and incorporates nanomicellar technology.
Sun Pharma North America CEO, Abhay Gandhi, said: 'Dry Eye Disease represents an area of high unmet medical need, with a significant number of patients who are currently untreated. The US FDA approval of CEQUA represents a long-awaited dry eye treatment option and is an important milestone in the development of Sun's Ophthalmics business. CEQUA, with its novel nanomicellar formulation for a proven dry eye medication, delivers a lipophilic molecule in a clear solution form.'
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT